 The FDA has granted priority review status to Amryt Pharmas NASDAQ: AMYT marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa EB. Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare genetic skin disorder characterized by blistering lesions on the skin and mucous membranes. 